Differences | China CER | EU MDR CER |
---|---|---|
Periodic update | Periodical update is required but updating frequency not clear | Class I: every 5 years Class II: every 2 years Class IIb implantable and III: annual |
Exemption |
|
No exemption |
Clinical evaluation plan | Not required | Required (also includes clinical development plan) |
Chinese literature search | Required | Not required |
State of the Art | Required and shall include intended clinical superiority | Required and shall be supported by a literature search report |
Comparison device |
|
|
Choice of comparison device |
|
|
Equivalence |
|
|
Equivalence justifications | Must be robust and supported by non-clinical or clinical data | Rationales would be sufficient in most cases |
PMCF | May required for some devices | Required |
1
|
Make Strategies for Clinical Evaluation |
2
|
Data Collection |
3
|
Writing and Review |
4
|
NMPA Review & Follow Up |
BradyKnows is leading in the clinical evaluation of cutting-edge products via innovative pathway. Examples are the World’s First integrated CT Linear Accelerator and China’s First MR-Linac.
BradyKnows is committed to the clinical evaluation of advanced medical devices to resolve the unmet clinical needs of millions of patients. Examples are implants for hearing aid and glaucoma.
BradyKnows is the expert for the clinical evaluation of Class III high risk devices. Examples are automated external defibrillator, orthopedic implants, and surgical robots.
Do you want to know the feasible clinical pathways for your device's China NMPA approval?
Click START to take the self-evaluation quiz.
START
China CER Feasibility Self-Evaluation
How do I know if my device is clinically exempted in China?